In this webinar, learn about the new National Immunisation Program (NIP) shingles vaccine Shingrix®, which from 1 November 2023 will replace Zostavax® for eligible people most at risk of complications from shingles (herpes zoster). Questions during the webinar will be answered by NCIRS experts either online or during the live question-and-answer panel.
Leading domestic and international clinicians and researchers will present on:
the disease burden of shingles in Australia
details about Shingrix®, including clinical trial results and mechanism of protection
the new Australian Shingrix® vaccination program, including eligibility for NIP-funded vaccine, with a focus on older people, people with immunocompromise and Aboriginal and Torres Strait Islander peoples
the US experience of implementing a national Shingrix® program.
Shingles NIP program advice
From 1 November 2023, there are changes to the shingles vaccination schedule under the National Immunisation Program (NIP). Key points:
From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the NIP schedule. The groups eligible to receive the free vaccine will also change. The NIP will fund a 2-dose course for eligible people.
Shingrix® is a non-live vaccine. It’s highly effective in the prevention of herpes zoster (shingles) and its complications, including post-herpetic neuralgia (PHN), in both immunocompetent and immunocompromised people.
Current reminder letters – adolescent overdue reminder letters are sent to individuals at 14.5 years, 17 years and 18 years of age.
New reminder letters – following the HPV vaccine schedule changes in February 2023, Services Australia will introduce two new overdue reminder letter milestones.
From early November 2023, additional reminder letters will be sent to individuals who are considered overdue for HPV vaccine at 21 years and 24 years of age. This will support catch-up vaccinations before individuals turn 26 years of age and are no longer eligible for free HPV vaccines.
Additionally, individuals aged between 24 years and 25 years and 8 months who are considered overdue for HPV vaccine will receive a one-off reminder letter in November 2023.
Men B vaccine – New AIR due and overdue rules
New AIR due and overdue rules for meningococcal B (men B) vaccine will be introduced for First Nations children up to 2 years of age. This will support the extension of the Bexsero® catch-up program, from mid-October 2023.
The new rules for men B will not impact family assistance payments.
Immunisation History Statements for First Nations children will display when they are due for men B vaccine.
Childhood overdue reminder letters will include men B when the vaccine is considered overdue.
View due date – vaccination providers will be able to view when a First Nations child is due for men B vaccine (on the AIR site or AIR integrated clinical software).
AIR overdue reports – men B antigen will be available to be selected when requesting overdue reports via the AIR site. This will help with identifying individuals who may require catch-up men B vaccinations.
The AIR cannot identify individuals who are medically at risk and eligible to receive the meningococcal B vaccine under the NIP. Providers should refer to the National Immunisation Program Schedule in the relevant state or territory for details regarding eligibility for meningococcal B vaccine funded under the NIP.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…